Flotetuzumab, a bispecific DART to CD3e and CD123, has been studied in the context of TP53 mutations in AML; a post hoc analysis of patients with TP53-altered R/R AML treated with flotetuzumab showed a CR in 47% of patients [120]. This evidence concerns the gene TP53 and acute myeloid leukemia.